X

Trial Profile

A Phase II Study of Pazopanib GW786034, NSC 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Ewing's sarcoma; Hepatoblastoma; Neuroblastoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
Focus Therapeutic Use
Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals

Most Recent Events

06 Dec 2019 Status changed from active, no longer recruiting to completed.
05 Dec 2019 This trial has been completed in Slovakia, Spain, and Hungary according to European Clinical Trials Database record.
24 Sep 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com